Gyre Therapeutics vs Zevra Therapeutics
Gyre Therapeutics and Zevra Therapeutics are similar in size: $117m and $106m of revenue in their latest fiscal years. Zevra Therapeutics grew faster (350.9% against 10.2%). Zevra Therapeutics kept more of each dollar of sales as profit: a net margin of 78.2% against 8.5%.
| Latest fiscal year | Gyre TherapeuticsGYRE, 2025 | Zevra TherapeuticsZVRA, 2025 |
|---|---|---|
| Revenue | $117m | $106m |
| Revenue growth | 10.2% | 350.9% |
| Net income | $9.9m | $83.2m |
| Operating margin | — | -59.1% |
| Net margin | 8.5% | 78.2% |
| Return on equity | 15.7% | 85.7% |
| Free cash flow | −$180,000 | −$2.4m |
| Cash | $49.2m | $62.4m |
| Total debt | $0 | $63.6m |
| Debt to equity | — | 41.1% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | — | 61 |
| Market value | $472m | $604m |
| Price vs our value range | — | — |
| Moat score | 9 (Weak) | 11 (Weak) |
| Insider trades, 12 months | 0 buys, 18 sales | 0 buys, 13 sales |